Neoantigen-targeted immunotherapy is a rapidly advancing field that holds great promise for
treating cancer. The recognition of antigens by immune cells is a crucial step in tumor …

Hematologic malignancies (HMs) pose a serious threat to patients' health and life, and the
five-year overall survival of HMs remains low. The lack of understanding of the pathogenesis …

Yin-Yang 1 (YY1) is a member of the GLI-Kruppel family of zinc finger proteins and plays a
vital dual biological role in cancer as an oncogene or a tumor suppressor during …

The reinvigoration of anti-tumor T cells in response to immune checkpoint blockade (ICB)
therapy is well established. Whether and how ICB therapy manipulates antibody-mediated …

Photothermal therapy (PTT) has shown great potential in cancer treatment for inducing
photothermal ablation and eliciting immune responses. However, PTT-triggered antitumor …

The pursuit of effective treatments for metastatic cancer is still one of the most intensive
areas of research in the biomedical field. In a not‐so‐distant past, the scientific community …

The treatment efficacies of conventional medications against colorectal cancer (CRC) are
restricted by a low penetrative, hypoxic, and immunosuppressive tumor microenvironment …

Therapeutics targeting immune checkpoints have achieved astonishing clinical success in
cancer treatment. However, these therapies can hardly adapt to immunologically “cold” …

Menstrual blood-derived mesenchymal stem cells (MenSCs) have great potential in
regenerative medicine. MenSC has received increasing attention owing to its impressive …

Most pituitary adenomas (PAs) are considered benign tumors, but approximately 0.2% can
present metastasis and are classified as pituitary carcinomas (PCs). Refractory PAs lie …